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Abstract
Background Identifying potentially inappropriate medici-
nes (PIMs) leading to adverse drug events may reduce the
risk of morbidity and mortality in older people.
Objective The aim of this study was to examine the re-
lationship between exposure to PIMs and risk of Fall-re-
lated hospitalisations (FRH) and frequency of primary care
visits in older New Zealanders.
Methods Pharmaceutical collections (2011), diagnostic
(2007–2011) and events (2012) information derived from
the National Minimum Datasets were used to extract de-
mographics, medication and diagnostic information for
537,387 individuals aged C65 years. Prescription and di-
agnostic information were matched through unique Na-
tional Health Index numbers. The updated Beers 2012
criteria were used to identify PIMs. Polypharmacy was
defined as five or more medicines dispensed concurrently
for C90 days.
Results Individuals exposed to one or more PIMs had an
increased risk of FRH with an incidence rate ratio (IRR) of
1.45 (95 % confidence interval [CI] 1.37–1.52) and a
greater number of primary care visits (IRR 1.15; 95 % CI
1.15–1.16). Individuals exposed to polypharmacy had an
IRR of 1.41 (95 % CI 1.33–1.50) for FRH and an IRR of
1.14 (95 % CI 1.13–1.15) for primary care visits.
Conclusion PIMs identified by the 2012 Beers criteria
showed an increased risk of FRH and a greater number of
primary care visits. Age C85 years and female sex were
identified as significant predictors of FRH and primary care
visits.
Key Points
Prevention of adverse drug events such as falls,
fractures and hospitalisations are clinically important
outcomes in people aged 65 years and older.
Potentially inappropriate medicines (PIMs) identified
by the 2012 Beers criteria showed an increased risk
of Fall-related hospitalisations (FRH) and a greater
number of primary care visits in people aged
C65 years living in New Zealand.
On a population level, Beers criteria can be a useful
screening tool to guide prescribing in older people.
1 Introduction
Prevention of adverse drug events (ADEs) including falls,
fractures and hospitalisations are important clinical out-
comes in people aged 65 years and older. Polypharmacy
(concomitant use of five or more medicines) is an indicator
for potentially inappropriate medicine use and has been
associated with adverse clinical outcomes in older people
[1]. Identifying exposures to potentially inappropriate
medicines (PIMs) that can lead to ADEs can be examined
by the use of criterion-based explicit screening tools [2, 3].
Beers criteria are a universally accepted explicit tool for
screening for PIMs in older people [2]. The Beers criteria
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have been updated since it was first developed in 1991, and
applied in various settings including residential care fa-
cilities, acute care and ambulatory care to identify high-risk
prescribing in older adults [2, 4–6]. Exposure to PIMs
determined by the Beers criteria has shown to be associated
with an increased risk of mortality, functional impairment,
hospitalisations, delirium, falls, fractures and adverse drug
events [7–10]. On the contrary, studies have disaffirmed
findings of adverse outcomes to exposure to PIMs listed in
the Beers criteria [11, 12]. Despite recognition of the
aforementioned limitations associated with Beers criteria,
including not considering drug–drug interactions, dose and
duration (overtreatment) and partial applicability interna-
tionally (prescribing patterns and drug availability), it still
remains one of the widely accepted criterion-based tools
for identifying high-risk prescribing in older people.
Corresponding to global trends, the New Zealand
population is aging and the total population will comprise of
approximately 22–30 % of people aged 65 years and older
by 2061 [13]. Prior studies have shown that a high proportion
of older people are prescribed multiple medicines, increasing
the risk of exposure to PIMs and potentially leading to ADEs
and consequently an increase in healthcare expenditure [9,
14]. These studies have examined PIMs use in older people;
however, outcomes data at a population level is limited [15].
Hence, the primary objective of this population-level study
was to examine the risk of fall-related hospitalisations and
primary care visits associated with PIMs use in people aged
65 years and older in New Zealand.
2 Design and Methods
Approval to conduct this study was obtained by the Human
Ethics Committee at the University of Otago, New Zeal-
and, ethical approval number 12/147.
2.1 Study Population and Data Source
Anonymous data on all older individuals aged 65 years and
above who were dispensed at least one prescription medi-
cine between January 1, 2011 through to December 31,
2011 were identified from the Pharmaceutical Claims Data
Mart (Pharms) dataset. The prescriptions data for 559,625
individuals representing approximately 98 % of the total
population of older New Zealanders was extracted. For
these individuals, demographic information such as sex,
date of birth and ethnicity, and prescription details such as
date of dispensing, medicine name, medicine dose, dosing
frequency and quantity supplied were extracted. The di-
agnoses were coded using the International Classification
of Diseases and Related Health Problems, Tenth Revision,
Australian Modification (ICD-10-AM). The diagnostic
information for 180,978 out of the 559,625 individuals was
either missing or unknown.
The following extracts were obtained from the Ministry
of Health to undertake this study:
1. Pharms extract files for 2011 contained information on
sex, date of birth, medicine, daily dose, frequency,
quantity, prioritised ethnicity and District Health
Board (DHB) of domicile.
2. National Minimum Data set (2007–2011): information
on hospitalisations, event start date (2012), event end
date (2012), diagnosis code (ICD-10), accident codes
(ICD-10), and procedure codes (ICD-10).
3. General Practitioner (primary care) visits (2012): date
of visit/s.
Pharms is used by the Pharmaceutical Management
Agency (PHARMAC) and the Ministry of Health of New
Zealand to administer payment to pharmacists for dispensing
medicines, as well as to assist PHARMAC in its management
of the national medicines budget. Pharms extracts are supplied
by the Ministry of Health with individual-level prescription
data with an encrypted National Health Index (NHI) code
which enables individual records to be linked between the
various national health data collections whilst still protecting
the identity of the individuals. The encryption is an algorithm
of the actual NHI. There is only a unique encrypted version of
each NHI, which is never changed, allowing linking of new
data with datasets previously extracted.
2.2 Potentially Inappropriate Medicines (PIMs)
Exposure
The updated Beers 2012 criteria were used to identify
PIMs, both independent of diagnosis and taking diagnosis
or dose into consideration. If an individual was dispensed
one or more medicine for any duration, at any given time,
the individual was said to have an exposure to PIMs. For
this study, criterions related to identifying PIMs in lower
urinary tract infections and peptic ulcer diseases were
modified. To categorise medicines inappropriate for use in
individuals with lower urinary tract symptoms and benign
prostatic hyperplasia (BPH), only BPH was used as a di-
agnosis rather than both the symptoms. Additionally, ICD-
10 codes for peptic and gastrojejunal ulcers were included
with history of gastric or duodenal ulcers.
2.3 Chronic Disease Score
Chronic Disease Score (CDS) is a risk-adjustment metric
established on patient demographics (age and sex) and
account of dispensed medicines [16]. The CDS was used to
compute scores for comorbidities as diagnostic information
was unavailable for approximately 33.7 % of the study
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population. The CDS was included as a covariate in the
regression model.
2.4 Polypharmacy
Polypharmacy in individuals was identified as the use of
more than five medicines dispensed concurrently for more
than or equal to a period of 90 days.
2.5 Assessing Clinical Outcomes (Falls-Related
Hospitalisation [FRH] and Primary Care Visits)
Anonymous linkages via encrypted NHI numbers were used
to match prescription data with FRH and primary care visits
data between January 1, 2012 and December 31, 2012.
2.6 Statistical Analyses
Means and standard deviations were reported for age and
number of medicines in the study population. Proportions
were reported for sex and ethnicity. The frequency of pri-
mary care visits and FRH were found to be over-dispersed
with the variance exceeding the mean. The Pearson good-
ness-of-fit tests confirmed the distribution of primary care
visits and falls significantly differed for a Poisson distribu-
tion, distribution, p value of\0.001 (Prob[ v2 [537,385]).
Hence, a negative binomial regression was used to model the
frequency of primary care visits and FRH. Covariates in-
cluding age, sex, chronic disease scores were common to all
regression models. These covariates have been previously
shown to be associated with falls and adverse outcomes in
older people [3]. The goodness-of-fit for negative binomial
regression models of FRH and primary care visits was
analysed. The McFadden’s adjusted R2 for FRH and primary
care visits were 0.074 and 0.023, respectively. The max-
imum likelihood (Cox-Snell) R2 for FRH and primary care
visits were 0.010 and 0.114, respectively. All statistical
analyses were conducted using Stata Corp Release 12. A
p\ 0.05 was regarded as statistically significant.
3 Results
A total of 537,387 individuals 65 years and older were
included in the study, of which 54.9 % were females with a
mean age of 74.7 years (±7.6). The prevalence of PIMs
dispensed was 40.39 % with 78.5 % of individuals dis-
pensed at least one PIM and 21.5 % dispensed two or more
PIMs in 2011. The most common PIMs dispensed to the
study population were diclofenac (6.0 %) and amitriptyline
(4.9 %), followed by ibuprofen (4.6 %), zopiclone (3.2 %)
and naproxen (3.0 %). The mean number of medicines
dispensed was 5.6 (±3.9) (Table 1).
The events (FRH) data for 2012 showed that 2.75 %
(14,804) of these individuals had had a FRH in 2012. Of
these individuals, 50.8 % (7525/14,804) had an exposure to
at least one PIM in 2011. Similarly, data for primary care
visits (2012) was matched for all individuals
(n = 537,387) showing that 64.7 % (n = 347,452) of in-
dividuals visited their general practitioner one or more
times during 2012. Of these individuals, 40.5 % (140,720/
347,452) had potentially been exposed to at least one PIM
in 2011.
On univariate analysis, PIMs exposure, defined as a
categorical variable, was lower in males than in females
(odds ratio [OR] 0.88; 95 % CI 0.87–0.89) and was greater
in Europeans (OR 1.39; 95 % CI 1.37–1.42) in comparison
with any other ethnic group. Approximately 30.90 % of
individuals were exposed to polypharmacy (OR 2.23; 95 %
CI 2.21–2.26).
Table 2 summarises the negative binomial regression
models used to demonstrate associations of FRH and pri-
mary care visits after adjusting for age, sex, CDS scores,
and exposure to PIMs. Exposure to PIMs was included in
Table 1 Characteristics of the study population (n = 537,387)
Characteristic Value PIMs exposure
OR (95 % CI)
Age (mean ± SD) 74.72 ± 7.60
Age (years)
65–74a 55.10 % 1
75–84 32.10 % 1.24 (1.23–1.26)
C85 12.80 % 1.42 (1.39–1.44)
Female sex 54.91 % 0.88 (0.87–0.89)
Ethnicity
Europeana 79.11 % 1
Ma¯ori 4.70 % 0.85 (0.82–0.87)
Asian 3.76 % 0.49 (0.47–0.51)
Pacific 2.64 % 0.63 (0.61–0.65)
MELAA 0.30 % 0.65 (0.53–0.81)
Others/unknown 9.49 % 0.72 (0.70–0.73)
Individuals exposed to PIMs C1 40.39 %
Mean total number of dispensed
medicines
5.64 ± 3.91
Chronic Disease Score (CDS) 6.04 ± 4.97 1.06 (1.06–1.06)
Individuals exposed to
polypharmacy
33.20 % 2.23 (2.21–2.26)
Individuals admitted with falls
(6 months after study period)
2.75 % 1.54 (1.49–1.60)
GP visits (12 months after study
period)
64.66 % 1.25 (1.24–1.27)
CI confidence interval, GP general practitioner, MELAA Middle
Eastern/Latin American/African, OR odds ratio, PIMs potentially
inappropriate medicine
a Reference category
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these models as a covariate. Demographic predictors such
as female sex (incidence rate ratio [IRR] 1.27; 95 % CI
1.20–1.34) and age C85 years (IRR 7.27; 95 % CI
6.78–7.79) were significant predictors of FRH. Individuals
having an increased chronic disease score also predicted an
increased risk of FRH and primary care visits.
Exposure to one or more PIMs showed an increased risk
of FRH (IRR 1.45; 95 % CI 1.37–1.53) and primary care
visits (IRR 1.15; 95 % CI 1.15–1.16). Individuals exposed
to polypharmacy had an IRR of 1.41 (95 % CI 1.37–1.52)
for FRH and IRR of 1.14 (95 % CI 1.15–1.16) for primary
care visits.
4 Discussion
This population-level study of older New Zealanders
identified that approximately 41 % of individuals aged
65 years and older were dispensed at least one PIM in 2011
and over 50 % of individuals with FRH in 2012 were ex-
posed to at least one PIM in 2011. Additionally, 40.5 % of
individuals with at least one primary care visit in 2012
were also exposed to one PIM in 2011. Age, sex, CDS,
polypharmacy and exposure to PIMs were all predictors of
FRH and the frequency of primary care visits in 2012.
Three of the top five PIMs dispensed were non-steroidal
anti-inflammatory drugs and it is well established that these
medicines have a potential to increase the risk of cardio-
vascular, renal and haematological adverse events in older
people [17, 18].
There are limitations to this study. Similar to other
global studies using the Beers criteria, not all medicines
listed were available in New Zealand or funded by
PHARMAC. In addition, only the first twenty diagnoses
were accessible from the minimum data set obtained from
the Ministry of Health. Additionally, medicines not funded
by PHARMAC and over-the-counter medicines not cap-
tured by Pharms may have underestimated the exposure to
PIMs in this study population. Furthermore, a retrospective
study design limits causal relationships between PIMs ex-
posure and adverse outcomes.
Our study showed an increased risk of FRH and primary
care visits associated with exposure to PIMs. This result is
consistent with findings that have linked exposure to PIMs
and polypharmacy to adverse health outcomes [10, 19, 20].
Klarin et al. [10] reported that community-dwelling older
people exposed to PIMs had an increased risk of hospi-
talisation. Previous studies have demonstrated the utility of
administrative health data to examine appropriateness of
prescribing [21–24].
The charge for fully subsidised medicines at the time of
this study was NZ$3, and very few prescriptions would
cost more than $3. Hence, a large proportion of dispensing
in this age group was captured by Pharms. Selection bias
may have been eliminated given that almost the entire
older population of New Zealand is captured in the Pharms
dataset. Another major strength was the availability of
ICD-10 codes which enabled linkage of prescription, di-
agnosis and events datasets.
This study is the first in New Zealand to examine the
relationship between exposure to PIMs and FRH and pri-
mary care visits at a population level. Congruent to the
findings from previous research, exposure to PIMs is as-
sociated with an increased risk of hospitalisations and poor
health outcomes [10, 25–27]. Use of such criteria can en-
able improved prescribing by flagging alerts into the
physician dispensing software or into electronic prescribing
software or into decision support systems maintained by
healthcare organisations.
5 Conclusion
Using the updated Beers 2012 criteria, exposure to PIMs
showed an association with FRH and frequency of primary
care visits. Age C85 years and female sex were identified
as significant predictors of FRH and primary care visits. On
a population level, Beers criteria may be a useful screening
tool to identify high-risk prescribing and reduce adverse
outcomes in older people.
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